Status:
UNKNOWN
Vascular Effects of Hesperidin in Metabolic Syndrome
Lead Sponsor:
University of Rome Tor Vergata
Conditions:
Endothelial Dysfunction
Metabolic Syndrome
Eligibility:
All Genders
20-55 years
Phase:
PHASE2
Brief Summary
It has been suggested that cardiovascular risk factors either independently or in cluster (metabolic syndrome) increase the risk of both type 2 diabetes (DM2) and cardiovascular diseases (CVD). Consum...
Eligibility Criteria
Inclusion
- Metabolic Syndrome (ATPIII criteria)
- BMI \<35
- Age 20-55
Exclusion
- History of cancer.
- History of cardiovascular diseases.
- Any other acute or chronic illness which requires administration of steroids or other drugs able to interfere with glucose or lipid metabolism.
Key Trial Info
Start Date :
November 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2010
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT00914251
Start Date
November 1 2008
End Date
December 1 2010
Last Update
June 17 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Rome Tor Vergata
Rome, Rome, Italy, 00133